Status:
COMPLETED
Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy
Lead Sponsor:
HonorHealth Research Institute
Conditions:
Adenocarcinoma of Pancreas
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
A pilot randomized feasibility trial with a blinded evaluator.
Detailed Description
Chemotherapy-induced peripheral neuropathy (CIPN) has a dose limiting effect which can greatly affect quality of life and often limits the amount of treatment patients can receive in treating their ca...
Eligibility Criteria
Inclusion
- Patients with adenocarcinoma of the pancreas who will receive chemotherapy with albumin bound paclitaxel plus gemcitabine containing combination
- Patients who have no prior evidence of peripheral neuropathy of the hands
- Age 18 years or older
- Able to sit for minimum of 30 minutes for hand therapy sessions
Exclusion
- Patients who have received at least one dose of chemotherapy with albumin bound paclitaxel plus gemcitabine during the past 6 months
- Patients taking duloxetine or gabapentin
- History of peripheral neuropathy of the hands due to chemotherapy, diabetes, or other causes
- Inability to sit for minimum of 30 minutes
- Documented cognitive problems limiting ability to participate in hand therapy
Key Trial Info
Start Date :
May 13 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT05374876
Start Date
May 13 2016
End Date
September 30 2021
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258